TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 28987002

Group type: EXPERIMENTAL
Intervention: Baseline procollagen type I amino-terminal propeptide (P1NP)
Number of subjects: 973

Group type: EXPERIMENTAL
Intervention: Baseline osteocalcin
Number of subjects: 973

Group type: EXPERIMENTAL
Intervention: Baseline C-terminal telopeptide of type I collagen (CTX)
Number of subjects: 973

Group type: EXPERIMENTAL
Intervention: Physical activity during sports activities
Number of subjects: 973

Group type: EXPERIMENTAL
Intervention: Mean annual aBMD changes
Number of subjects: 973
Study: 28988157

Group type: EXPERIMENTAL
Intervention: Severe/major bleeding (measured by GUSTO, TIMI, ACUITY, and BARC scales)
Number of subjects: 25107

Group type: EXPERIMENTAL
Intervention: Blood transfusion requirement
Number of subjects: 25107

Group type: EXPERIMENTAL
Intervention: Mild/minor bleeding
Number of subjects: 25107

Group type: EXPERIMENTAL
Intervention: Bleeding definitions (GUSTO, TIMI, ACUITY, BARC)
Number of subjects: 25107
Study: 28988183

Group type: EXPERIMENTAL
Intervention: Endo-CABG
Number of subjects: 150

Group type: COMPARATOR
Intervention: Percutaneous coronary intervention
Number of subjects: 150

Group type: COMPARATOR
Intervention: Healthy volunteer group
Number of subjects: 150
Study: 28988184

Group type: EXPERIMENTAL
Intervention: Frailty assessment in older patients undergoing emergency laparotomy
Number of subjects: 500
Study: 28988198

Group type: EXPERIMENTAL
Intervention: Selective ESD (S-ESD)
Number of subjects: 1765

Group type: EXPERIMENTAL
Intervention: Universal ESD (U-ESD)
Number of subjects: 1765

Group type: COMPARATOR
Intervention: Wide-field endoscopic mucosal resection (WF-EMR)
Number of subjects: 1765
Study: 28988211

Group type: EXPERIMENTAL
Intervention: Oestrogen-alone PHT
Number of subjects: 30034

Group type: EXPERIMENTAL
Intervention: Oestrogen and progesterone PHT
Number of subjects: 30034

Group type: COMPARATOR
Intervention: Younger age at menopause (<45 years)
Number of subjects: 30034

Group type: COMPARATOR
Intervention: Menopausal age 45-49 years
Number of subjects: 30034

Group type: COMPARATOR
Intervention: Menopausal age 50-54 years
Number of subjects: 30034

Group type: COMPARATOR
Intervention: Menopausal age >54 years
Number of subjects: 30034
Study: 28988331

Group type: EXPERIMENTAL
Intervention: Herpes zoster with post-herpetic neuralgia
Number of subjects: 412

Group type: COMPARATOR
Intervention: Herpes zoster without complications
Number of subjects: 412

Group type: EXPERIMENTAL
Intervention: Overall economic burden analysis
Number of subjects: 412
Study: 28988934

Group type: EXPERIMENTAL
Intervention: WTX101 monotherapy at a starting dose of 15-60 mg/day for the first 4-8 weeks, with response-guided individualised dosing for the remaining weeks up to week 24.
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: WTX101 monotherapy
Number of subjects: 28
Study: 28989060

Group type: EXPERIMENTAL
Intervention: Liver transplantation for HCC
Number of subjects: 1359

Group type: EXPERIMENTAL
Intervention: Competing-risk regression analysis
Number of subjects: 1359

Group type: EXPERIMENTAL
Intervention: Cumulative incidence analysis
Number of subjects: 1359
Study: 28989706

Group type: EXPERIMENTAL
Intervention: Standard Dialectical Behaviour Therapy (DBT) for 12 months
Number of subjects: 54
Study: 28990201

Group type: EXPERIMENTAL
Intervention: FIBTEM MCF values <8 mm
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: FIBTEM MCF values >8 mm
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: FIBTEM MCF values >10 mm
Number of subjects: 86

Group type: COMPARATOR
Intervention: FIBTEM MCF
Number of subjects: 86
Study: 28990589

Group type: EXPERIMENTAL
Intervention: Simple anthropometric measures (weight and weight/length)
Number of subjects: 251

Group type: EXPERIMENTAL
Intervention: Skinfold measures
Number of subjects: 251
Study: 28991061

Group type: EXPERIMENTAL
Intervention: 0.5% Ropivacaine, initial volume 30 mL, adjusted by 2 mL based on previous subject's response
Number of subjects: 26
Study: 28991112

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine administered over 15 minutes, dosage determined by the Dixon up-and-down method.
Number of subjects: 79
Study: 28991404

Group type: EXPERIMENTAL
Intervention: Inactivated trivalent influenza vaccine (TIV)
Number of subjects: 20
Study: 28991876

Group type: EXPERIMENTAL
Intervention: Dedicated Electronic-Health-Record providing feedback
Number of subjects: 1752
Study: 28991900

Group type: EXPERIMENTAL
Intervention: VEGF-A in serum
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: VEGF-C in plasma
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: PLGF in plasma
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: VEGF-A in plasma
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Circadian levels of VEGFs
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Single morning measurement of systemic VEGF levels
Number of subjects: 20
Study: 28992094

Group type: EXPERIMENTAL
Intervention: In-center nocturnal hemodialysis (INHD), 7-8 hours/session, three times/week
Number of subjects: 67
Study: 28992527

Group type: EXPERIMENTAL
Intervention: MDD patients (n = 100)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Healthy controls (n = 100)
Number of subjects: 100
Study: 28993391

Group type: EXPERIMENTAL
Intervention: Integrated Community of Care (ICoC)
Number of subjects: 250

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 250
Study: 28994184

Group type: EXPERIMENTAL
Intervention: High myopic cataract (HMC) lenses
Number of subjects: 0

Group type: COMPARATOR
Intervention: Age-related cataract (ARC) lenses
Number of subjects: 0
Study: 28994660

Group type: EXPERIMENTAL
Intervention: Rilpivirine (RPV) 25 mg, once daily
Number of subjects: 20

Group type: COMPARATOR
Intervention: Efavirenz (EFV)
Number of subjects: 20
Study: 29016235

Group type: EXPERIMENTAL
Intervention: Telemedicine support group intervention using encrypted tablet-based videoconferencing.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Telemedicine support group intervention
Number of subjects: 0
Study: 29016504

Group type: EXPERIMENTAL
Intervention: Evacuation proctography
Number of subjects: 131

Group type: EXPERIMENTAL
Intervention: MRI
Number of subjects: 131

Group type: EXPERIMENTAL
Intervention: Transperineal ultrasonography
Number of subjects: 131

Group type: EXPERIMENTAL
Intervention: Endovaginal ultrasonography
Number of subjects: 131

Group type: EXPERIMENTAL
Intervention: Transperineal ultrasonography and Endovaginal ultrasonography
Number of subjects: 131
Study: 29016506

Group type: EXPERIMENTAL
Intervention: Contraceptive practices (no intercourse, protected intercourse, unprotected intercourse, or tried to conceive) classified based on the preceding year.
Number of subjects: 710

Group type: EXPERIMENTAL
Intervention: Conception rates across follow-up.
Number of subjects: 710

Group type: EXPERIMENTAL
Intervention: Age, marital status, and preoperative importance of future pregnancy as factors influencing early conception.
Number of subjects: 710
Study: 29016755

Group type: EXPERIMENTAL
Intervention: Catheter ablation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cardioversion
Number of subjects: 0
Study: 29016813

Group type: EXPERIMENTAL
Intervention: AtriClip device for epicardial left atrial appendage (LAA) occlusion
Number of subjects: 291
Study: 29016998

Group type: EXPERIMENTAL
Intervention: Cabozantinib 140 mg/day
Number of subjects: 152

Group type: EXPERIMENTAL
Intervention: Cabozantinib 100 mg/day
Number of subjects: 152

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 152
Study: 29017455

Group type: EXPERIMENTAL
Intervention: Remifentanil adjusted to approximately 6.5 ng/mL before head fixation
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Baseline hemodynamic values recorded before head fixation
Number of subjects: 50
Study: 29017461

Group type: EXPERIMENTAL
Intervention: Early discharge after TF-TAVI
Number of subjects: 0

Group type: COMPARATOR
Intervention: Late discharge after TF-TAVI
Number of subjects: 0
Study: 29017466

Group type: EXPERIMENTAL
Intervention: E. coli isolates from patients with uUTI
Number of subjects: 485

Group type: EXPERIMENTAL
Intervention: E. coli isolates from patients with cUTI
Number of subjects: 485

Group type: EXPERIMENTAL
Intervention: E. coli from uUTI and cUTI
Number of subjects: 485
Study: 29017471

Group type: EXPERIMENTAL
Intervention: Self-admission program
Number of subjects: 16
Study: 29017605

Group type: EXPERIMENTAL
Intervention: Collaborative shared care (CSC) intervention program implemented by complementary alternative health providers (CAPs) and primary health care providers (PHCPs)
Number of subjects: 296

Group type: COMPARATOR
Intervention: Care as usual (CAU)
Number of subjects: 296

Group type: EXPERIMENTAL
Intervention: Collaborative shared care (CSC) intervention
Number of subjects: 296
Study: 29017776

Group type: EXPERIMENTAL
Intervention: Edwards SAPIEN XT transcatheter heart valve system
Number of subjects: 46
Study: 29017845

Group type: EXPERIMENTAL
Intervention: Participants with self-reported DH (n=272) who spent ≥10min eating fruit per sitting (n=46)
Number of subjects: 600

Group type: EXPERIMENTAL
Intervention: Participants with self-reported DH (n=272) who had a drinking habit such as sipping, swishing or holding drinks in the mouth (n=72)
Number of subjects: 600

Group type: EXPERIMENTAL
Intervention: Participants with self-reported DH (n=272) using a soft toothbrush (n=36)
Number of subjects: 600

Group type: COMPARATOR
Intervention: Frequency of daily toothbrushing
Number of subjects: 600

Group type: COMPARATOR
Intervention: Dietary acid intake
Number of subjects: 600
Study: 29017991

Group type: EXPERIMENTAL
Intervention: Gamified Web-based mobile service with wrist-worn physical activity monitor (Polar Active) providing feedback and fitness guidelines.
Number of subjects: 496

Group type: COMPARATOR
Intervention: Control group with wrist-worn monitor providing only time of day, no feedback.
Number of subjects: 496
Study: 29017994

Group type: EXPERIMENTAL
Intervention: BPTrack, a clinical pharmacist-led mHealth intervention for hypertension management, involving home blood pressure monitoring and medication adherence over a 12-week period.
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: BPTrack intervention
Number of subjects: 25
Study: 29018077

Group type: EXPERIMENTAL
Intervention: Venetoclax
Number of subjects: 0
Study: 29018174

Group type: EXPERIMENTAL
Intervention: NT-proBNP levels in patients with AF
Number of subjects: 14737

Group type: COMPARATOR
Intervention: NT-proBNP levels in patients without AF
Number of subjects: 14737

Group type: EXPERIMENTAL
Intervention: Predictive value of NT-proBNP for adverse cardiovascular outcomes
Number of subjects: 14737
Study: 29018317

Group type: EXPERIMENTAL
Intervention: JAKE® Multimodal Data Capture System
Number of subjects: 0
Study: 29018526

Group type: EXPERIMENTAL
Intervention: Nintedanib
Number of subjects: 600

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 600
Study: 29018537

Group type: COMPARATOR
Intervention: AMG 811 (6, 20 or 60 mg)
Number of subjects: 56

Group type: COMPARATOR
Intervention: AMG 811 (20, 60 or 120 mg)
Number of subjects: 56

Group type: COMPARATOR
Intervention: AMG 811
Number of subjects: 56
Study: 29018540

Group type: EXPERIMENTAL
Intervention: Individualised diet eliminating foods with positive assay results and allowing foods with negative assay results
Number of subjects: 58

Group type: COMPARATOR
Intervention: Individualised diet eliminating foods with negative assay results and allowing foods with positive assay results
Number of subjects: 58
Study: 29018564

Group type: EXPERIMENTAL
Intervention: Adalimumab plus methotrexate
Number of subjects: 0

Group type: COMPARATOR
Intervention: Methotrexate alone
Number of subjects: 0
Study: 29020217

Group type: EXPERIMENTAL
Intervention: Pentamidine secondary prophylaxis (PSP) for 12 months
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: Post-PSP follow-up for 1 year
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: Pentamidine secondary prophylaxis (PSP)
Number of subjects: 74
Study: 29020221

Group type: EXPERIMENTAL
Intervention: High CXCL9 levels in maternal peripheral blood during pregnancy
Number of subjects: 638

Group type: EXPERIMENTAL
Intervention: High IL-10 levels in maternal blood at delivery
Number of subjects: 638

Group type: EXPERIMENTAL
Intervention: Increased IL-1β levels in placental blood
Number of subjects: 638
Study: 29020260

Group type: EXPERIMENTAL
Intervention: Low 3V-FFR group
Number of subjects: 1136

Group type: EXPERIMENTAL
Intervention: Low 3V-FFR
Number of subjects: 1136

Group type: COMPARATOR
Intervention: High 3V-FFR group
Number of subjects: 1136
Study: 29020286

Group type: EXPERIMENTAL
Intervention: Pre-engraftment Gram-negative bacteremia (GNB) in allo-HSCT
Number of subjects: 2743

Group type: EXPERIMENTAL
Intervention: Pre-engraftment Gram-negative bacteremia (GNB) in auto-HSCT
Number of subjects: 2743
Study: 29020310

Group type: EXPERIMENTAL
Intervention: Levofloxacin prophylaxis
Number of subjects: 344

Group type: COMPARATOR
Intervention: Other prophylaxis regimens
Number of subjects: 344

Group type: COMPARATOR
Intervention: No prophylaxis
Number of subjects: 344
Study: 29020361

Group type: EXPERIMENTAL
Intervention: Immediate ART (Tenofovir plus emtricitabine/lamivudine)
Number of subjects: 2052
Study: 29020364

Group type: EXPERIMENTAL
Intervention: Fluoroquinolone prophylaxis
Number of subjects: 591

Group type: EXPERIMENTAL
Intervention: Allogeneic HSCT (allo-HSCT)
Number of subjects: 591

Group type: EXPERIMENTAL
Intervention: Infections caused by resistant bacteria
Number of subjects: 591

Group type: COMPARATOR
Intervention: Resistance rates
Number of subjects: 591

Group type: EXPERIMENTAL
Intervention: Multivariable analysis
Number of subjects: 591
Study: 29020367

Group type: EXPERIMENTAL
Intervention: SYNTAX-II strategy
Number of subjects: 454
Study: 29020401

Group type: EXPERIMENTAL
Intervention: T2MI patients
Number of subjects: 1548

Group type: COMPARATOR
Intervention: T1MI patients
Number of subjects: 1548

Group type: EXPERIMENTAL
Intervention: Diagnostic prediction model for T2MI
Number of subjects: 1548

Group type: EXPERIMENTAL
Intervention: Predictors for T2MI
Number of subjects: 1548

Group type: EXPERIMENTAL
Intervention: Score based on predictors
Number of subjects: 1548
Study: 29020583

Group type: EXPERIMENTAL
Intervention: Glecaprevir and pibrentasvir for 12 weeks
Number of subjects: 104
Study: 29020998

Group type: EXPERIMENTAL
Intervention: High SHMT2 protein expression
Number of subjects: 801

Group type: EXPERIMENTAL
Intervention: High ASCT2 protein expression
Number of subjects: 801
Study: 29021228

Group type: EXPERIMENTAL
Intervention: Allogeneic hematopoietic cell transplantation (HCT)
Number of subjects: 100
Study: 29021813

Group type: EXPERIMENTAL
Intervention: Phytosterols 800 mg
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Red yeast rice standardized to contain 5 mg monacolins
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Combination of phytosterols and red yeast rice
Number of subjects: 90
Study: 29023473

Group type: EXPERIMENTAL
Intervention: Ticagrelor 180 mg loading dose
Number of subjects: 73
Study: 29023494

Group type: EXPERIMENTAL
Intervention: Everolimus
Number of subjects: 112
Study: 29024428

Group type: EXPERIMENTAL
Intervention: Bariatric surgery
Number of subjects: 53
Study: 29025008

Group type: EXPERIMENTAL
Intervention: Bisoprolol 5 mg qd
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Carvedilol 12.5 mg bid
Number of subjects: 18

Group type: COMPARATOR
Intervention: Carvedilol with ICS/LABA
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Carvedilol with ICS/LABA/LAMA
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Bisoprolol with ICS/LABA
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Carvedilol with inhaled LAMA (tiotropium) and LABA (formoterol)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Carvedilol with LABA alone
Number of subjects: 18
Study: 29025041

Group type: EXPERIMENTAL
Intervention: Presence of myofascial trigger points (TrPs)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Widespread pressure pain sensitivity
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Mechanosensitivity of neural tissue
Number of subjects: 40
Study: 29025767

Group type: EXPERIMENTAL
Intervention: Daratumumab
Number of subjects: 0
Study: 29026685

Group type: EXPERIMENTAL
Intervention: Carfilzomib infusion (27 and 56 mg/m2)
Number of subjects: 77
Study: 29027127

Group type: EXPERIMENTAL
Intervention: A/BPO + SEM (supplementary patient education material)
Number of subjects: 97

Group type: COMPARATOR
Intervention: A/BPO + SOCPE + more visits
Number of subjects: 97

Group type: COMPARATOR
Intervention: A/BPO + SOCPE only
Number of subjects: 97

Group type: EXPERIMENTAL
Intervention: A/BPO + SEM
Number of subjects: 97

Group type: COMPARATOR
Intervention: A/BPO + more visits
Number of subjects: 97

Group type: COMPARATOR
Intervention: A/BPO alone
Number of subjects: 97
Study: 29027195

Group type: EXPERIMENTAL
Intervention: abiraterone acetate/prednisone
Number of subjects: 87
Study: 29027607

Group type: EXPERIMENTAL
Intervention: Patient-reported outcome measure (PRO) for barriers to antiretroviral therapy (ART) adherence
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: PRO for 'passive' patients
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: PRO for 'misleading' patients
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: PRO for 'stoic' patients
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: PRO for 'hedonistic' patients
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: PRO for 'obsessive' patients
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: PRO for 'overburdened' patients
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: General PRO recommendations
Number of subjects: 31
Study: 29027812

Group type: EXPERIMENTAL
Intervention: Accu-Chek Connect diabetes management system
Number of subjects: 87
Study: 29027863

Group type: EXPERIMENTAL
Intervention: Postcontrast FLAIR imaging
Number of subjects: 23

Group type: COMPARATOR
Intervention: 3D-GRE imaging
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: FLAIR as a complementary tool to 3D-GRE
Number of subjects: 23
Study: 29028159

Group type: EXPERIMENTAL
Intervention: Human bocavirus 1 (HBoV1) infection confirmed serologically
Number of subjects: 759

Group type: EXPERIMENTAL
Intervention: Detection of respiratory viruses by PCR
Number of subjects: 759

Group type: EXPERIMENTAL
Intervention: Detection of HBoV1-DNA by PCR
Number of subjects: 759

Group type: EXPERIMENTAL
Intervention: Detection of sole HBoV1
Number of subjects: 759

Group type: EXPERIMENTAL
Intervention: Acute HBoV1 infection in cases with another virus
Number of subjects: 759

Group type: EXPERIMENTAL
Intervention: Acute HBoV1 infection in sole virus detection
Number of subjects: 759
Study: 29028274

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 29028662

Group type: EXPERIMENTAL
Intervention: Stool Xpert
Number of subjects: 165

Group type: EXPERIMENTAL
Intervention: Urine LAM
Number of subjects: 165

Group type: EXPERIMENTAL
Intervention: Sputum/Gastric aspirate Xpert
Number of subjects: 165

Group type: EXPERIMENTAL
Intervention: Stool Xpert (in severe immunosuppression)
Number of subjects: 165
Study: 29028788

Group type: EXPERIMENTAL
Intervention: Pembrolizumab 2 mg/kg every 3 weeks
Number of subjects: 979
Study: 29028802

Group type: EXPERIMENTAL
Intervention: PCV7/PPV23
Number of subjects: 132

Group type: EXPERIMENTAL
Intervention: PPV23 only
Number of subjects: 132

Group type: EXPERIMENTAL
Intervention: No pneumococcal vaccines
Number of subjects: 132

Group type: COMPARATOR
Intervention: All groups
Number of subjects: 132

Group type: EXPERIMENTAL
Intervention: PCV7 and/or PPV23 immunization
Number of subjects: 132

Group type: EXPERIMENTAL
Intervention: PPV23 immunization
Number of subjects: 132
Study: 29028910

Group type: EXPERIMENTAL
Intervention: Intravascular microdialysis
Number of subjects: 23
Study: 29028933

Group type: EXPERIMENTAL
Intervention: Paced breathing at 6 bpm
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Paced breathing at 10 bpm
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Paced breathing at 15 bpm
Number of subjects: 14
Study: 29028966

Group type: EXPERIMENTAL
Intervention: STI screening offered to participants
Number of subjects: 214

Group type: EXPERIMENTAL
Intervention: Engaging in insertive anal intercourse
Number of subjects: 214

Group type: EXPERIMENTAL
Intervention: Engaging in both insertive and receptive anal intercourse
Number of subjects: 214

Group type: EXPERIMENTAL
Intervention: Presence of STI symptoms
Number of subjects: 214

Group type: EXPERIMENTAL
Intervention: Condomless sex
Number of subjects: 214

Group type: EXPERIMENTAL
Intervention: Any recent drug use
Number of subjects: 214
Study: 29029064

Group type: EXPERIMENTAL
Intervention: LAIV
Number of subjects: 1012

Group type: EXPERIMENTAL
Intervention: IIV
Number of subjects: 1012
Study: 29029122

Group type: EXPERIMENTAL
Intervention: HZ/su (adjuvanted herpes zoster subunit vaccine), 2 doses 2 months apart
Number of subjects: 430

Group type: EXPERIMENTAL
Intervention: HZ/su (adjuvanted herpes zoster subunit vaccine)
Number of subjects: 430
Study: 29029127

Group type: EXPERIMENTAL
Intervention: GBS vaccine (0.5, 2.5, or 5.0 μg of each of 3 CRM197-glycoconjugates)
Number of subjects: 317

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 317

Group type: EXPERIMENTAL
Intervention: GBS vaccine
Number of subjects: 317
Study: 29029131

Group type: EXPERIMENTAL
Intervention: AA infusion
Number of subjects: 21

Group type: COMPARATOR
Intervention: Saline infusion (control)
Number of subjects: 21
Study: 29029190

Group type: EXPERIMENTAL
Intervention: rhIGF-1
Number of subjects: 5
Study: 29029562

Group type: EXPERIMENTAL
Intervention: Behavioral Parent Training (BPT) - Helping the Noncompliant Child (HNC) program
Number of subjects: 15
Study: 29029833

Group type: EXPERIMENTAL
Intervention: Fluorodeoxyglucose (FDG) uptake
Number of subjects: 0
Study: 29030346

Group type: EXPERIMENTAL
Intervention: ADD-RS=0/DD- strategy
Number of subjects: 1850

Group type: EXPERIMENTAL
Intervention: ADD-RS ≤1/DD- strategy
Number of subjects: 1850

Group type: COMPARATOR
Intervention: D-dimer (DD) test
Number of subjects: 1850
Study: 29030361

Group type: EXPERIMENTAL
Intervention: Certolizumab pegol (CZP)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Umbilical cord samples
Number of subjects: 16
Study: 29030383

Group type: EXPERIMENTAL
Intervention: Adaptive artificial pancreas (AP) system
Number of subjects: 30
Study: 29030401

Group type: EXPERIMENTAL
Intervention: Whole Genome Sequencing (WGS)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Multigene Panel Testing
Number of subjects: 41
Study: 29030421

Group type: EXPERIMENTAL
Intervention: Escitalopram (n=159)
Number of subjects: 301

Group type: COMPARATOR
Intervention: Placebo (n=142)
Number of subjects: 301

Group type: EXPERIMENTAL
Intervention: 5-HTTLPR polymorphisms
Number of subjects: 301
Study: 29030503

Group type: EXPERIMENTAL
Intervention: Blended therapy combining face-to-face problem solving and a smartphone app
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Blended therapy
Number of subjects: 7
Study: 29030717

Group type: EXPERIMENTAL
Intervention: Cigarette smoking status (baseline smoking status)
Number of subjects: 0